CD38 and Miyoshi myopathy: These clinical observations suggest that real‐time, whole‐body measurements of CD38 expression using molecularly targeted PET radiotracers could provide more accurate information for guiding anti‐CD38 therapies in MM than current single‐time point and single‐lesion flow cytometry measurements.